T2 Biosystems Announces Third Quarter 2024 Financial Results

1 day ago · TTOO. T2 Biosystems, Inc. Achieved 34% quarterly revenue growth compared to the prior year period. LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 …

CouponFollow Extension

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

1 day ago · TTOO. T2 Biosystems, Inc. Achieved 34% quarterly revenue growth compared to the prior year period. LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 …

yahoo.com

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

1 day ago · Third Quarter 2024 Financial Results Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew …

businessinsider.com

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

1 day ago · Achieved 34% quarterly revenue growth compared to the prior year period. LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. …

manilatimes.net

35%
OFF

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial …

1 week from now

Oct 7, 2024 · Achieved 35% increase in total revenue compared to prior year periodLEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a …

yahoo.com

34%
OFF

T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript

1 week from now

1 day ago · The T2 Biosystems team generated third quarter revenue of $2.0 million, representing 34% growth compared to the prior year period. Growth was driven by $1.4 million of sepsis …

seekingalpha.com

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

2 days ago · Third Quarter 2024 Financial Results Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew …

menafn.com

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

1 day ago · T2 Biosystems (NASDAQ:TTOO) reported Q3 2024 financial results with total revenue of $2.0 million, up 34% year-over-year. Sepsis test panel revenue reached $1.4 …

stocktitan.net

35%
OFF

T2 Biosystems Announces Preliminary Third Quarter 2024

1 week from now

Oct 7, 2024 · T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results Achieved 35% increase in total revenue compared to prior year period October 07, 2024 09:00 …

globenewswire.com

49%
OFF

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial …

1 week from now

Oct 7, 2024 · The Company now expects fourth quarter 2024 total sepsis product revenue of $2.5 million to $3.5 million, representing growth of 49% to 109% compared to the fourth quarter of …

tmcnet.com

34%
OFF

T2 Biosystems, Inc. (TTOO) 8-K Earnings Release, Other Events

1 week from now

1 day ago · T2 Biosystems Announces Third Quarter 2024 Financial Results . Achieved 34% quarterly revenue growth compared to the prior year period . LEXINGTON, Mass., November …

last10k.com

35%
OFF

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial ...

1 week from now

Oct 7, 2024 · Achieved 35% increase in total revenue compared to prior year period. LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: …

biospace.com

FAQs about T2 Biosystems Announces Third Quarter 2024 Financial Results Coupon?

What did T2 Biosystems do in Q3 2024?

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the third quarter 2024. Recent Financial and Operational Highlights (unaudited) ...

How much money did t2biothreat raise in Q4 2024?

The Company raised $4.3 million in net proceeds with our ATM during the quarter and $3.2 million since September 30, 2024. The Company expects fourth quarter 2024 total sepsis product revenue of $2.5 million to $3.5 million. This target does not include potential sales of the T2Biothreat™ Panel or the T2Lyme™ Panel. ...

What is t2biothreat's fourth quarter 2024 revenue guidance?

The Company now expects fourth quarter 2024 total sepsis product revenue of $2.5 million to $3.5 million, representing growth of 49% to 109% compared to the fourth quarter of 2023. The Company’s 2024 revenue guidance consists entirely of sepsis product revenue and does not include potential sales of the T2Biothreat™ Panel or the T2Lyme™ Panel. ...

Who is T2 Biosystems?

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. ...

How did sepsis ® perform in the third quarter of 2024?

Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew 34% compared to the prior year period, led by T2Bacteria ®. ...

What are the price targets for T2 Biosystems?

According to 3 Wall Street analysts in the last 3 months, the average price target for T2 Biosystems is $0.16, with a high forecast of $0.20 and a low forecast of $0.12. This represents a potential change of 126.63% from the last price of $0.07. ...